ArticleDiabetes, obesity & metabolism2020

The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.

Rosalie A Scholtes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.